According to Future Market Insights' latest research, the global proton pump inhibitors market is currently valued at around US$ 2.8 Billion and is anticipated to progress at a CAGR of 5.2% to reach US$ 4.9 Billion by 2033. Omeprazole has emerged as the dominant player in the global market, capturing a market share of around 28.5% in 2022. These findings highlight the significant growth potential of the proton pump inhibitors market, driven by increasing demand for effective acid-suppressing medications for conditions like gastroesophageal reflux disease (GERD).
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 2.8 Billion |
| Market Value 2023 | US$ 3.0 Billion |
| Market Value 2033 | US$ 4.9 Billion |
| CAGR 2023 to 2033 | 5.2% |
| Market Share of Top 5 Countries | 56.0% |
| Key Market Players | AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eisai Inc., GlaxoSmithKline PLC, Pfizer Inc., Takeda Pharmaceuticals, Sanofi SA, Perrigo Company PLC, Dr. Reddy's Laboratories, Redhill Pharma Limited, Cipla Limited |
Proton pump inhibitors (PPIs) are a class of medications commonly used to treat conditions related to excessive stomach acid production. They work by inhibiting the action of the gastric proton pump, thereby reducing acid secretion in the stomach. PPIs are primarily prescribed for gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related disorders.
PPIs have revolutionized the management of acid-related disorders, providing effective relief and improving the quality of life for millions of individuals worldwide. The market continues to evolve with advancements in drug formulations, personalized medicine approaches, and an increasing focus on patient convenience and adherence.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global proton pump inhibitors market expanded at a CAGR of 4.1% over the last five years (2017-2022).
In 2022, the proton pump inhibitors market accounted for over 7.4% of the total global gastrointestinal therapeutics market, valued at US$ 38.1 Billion in 2022.
The prevalence of gastrointestinal disorders has globally increased due to factors like poor dietary choices, sedentary lifestyles, stress, and an aging population. Diets high in fat, spice, and acidity, along with irregular eating patterns, can potentially lead to acid reflux and digestive issues.
The growing awareness and diagnosis of gastroesophageal reflux disease (GERD) have fuelled the demand for proton pump inhibitors (PPIs). As people become more aware of GERD symptoms and their impact on their health, there is an increased inclination to seek medical attention and obtain an accurate diagnosis.
This heightened awareness has led to a surge in demand for PPIs, which are highly effective in managing GERD by reducing gastric acid production. Healthcare providers and patients alike recognize the importance of treating GERD to alleviate symptoms and prevent complications, driving the growth of the PPI market.
The expansion of key players into emerging markets is a significant driver of the demand for the proton pump inhibitor (PPI) market. As pharmaceutical companies expand their presence in these markets, there is an increased accessibility and availability of PPI medications to a larger population.
Emerging markets often have a growing middle class, improving healthcare infrastructure, and rising disposable incomes, which contribute to the increased demand for PPIs. This expansion not only drives market growth but also ensures that patients in these regions have access to essential medications for the management of gastrointestinal disorders. In conclusion, the strategic expansion of key players into emerging markets is a key factor propelling the demand for the proton pump inhibitors market.
The rise in healthcare expenditure, particularly in emerging economies, presents a significant opportunity for proton pump inhibitor (PPI) market manufacturers. Increased healthcare spending enables enhanced access to medical services, including diagnosis and treatment for gastrointestinal ailments. This accessibility encourages patients to seek medical assistance, leading to higher prescription rates for PPIs and driving market expansion.
Moreover, the growth in healthcare spending contributes to increased research and development efforts within the pharmaceutical sector. Pharmaceutical companies can allocate resources to develop novel and improved PPI formulations, conduct clinical studies, and gather empirical data to demonstrate the efficacy and safety of their products.
Furthermore, technological advancements in the field of proton pump inhibitors (PPIs) offer key players in the market various opportunities. Advancements in formulation technologies enable the development of novel drug delivery systems that enhance drug stability, bioavailability, and targeted delivery.
Manufacturers can also leverage advancements in molecular biology and genomics to develop personalized PPI therapies tailored to individual patients. Additionally, the use of artificial intelligence and big data analytics can aid in drug discovery, optimize dosing regimens, and improve treatment outcomes. These technological opportunities empower manufacturers to develop more effective and patient-centric PPI products, thereby driving their growth and success in the market.
Principal Consultant
Introduction of Generic Medicines into the Market
The recent expiration of patents for certain proton pump inhibitor (PPI) medications has led to the introduction of generic versions into the market. The availability of these generic alternatives may impact the demand for branded PPIs, particularly if the branded products do not offer significant distinguishing features or benefits.
Generic versions of branded PPIs are typically priced lower due to reduced costs associated with research and development, as well as the absence of patent-related charges. This creates a highly competitive environment where healthcare providers, insurers, and patients are inclined to choose the more affordable generic alternatives.
While PPIs are generally considered safe and well-tolerated, long-term use or misuse can lead to potential adverse effects such as increased risk of fractures, infections, and nutrient deficiencies. Safety concerns associated with PPIs can discourage some individuals from using or continuing PPI therapy, thus restraining the demand.
The United States holds a significant share of around 34.4% in the North American market for proton pump inhibitors (PPIs) in 2022, with projections of continued profitable growth in this region. The aging demographic in the U.S. is noteworthy, as research suggests that the elderly population is more prone to gastrointestinal disorders and may require prolonged use of PPIs for treatment. As the aging population increases, there is a corresponding rise in demand for PPIs in the United States.
Furthermore, the United States has a prevalent consumer-conscious culture, which is evident in the direct-to-consumer advertising of prescription drugs, including PPIs. According to the American Gastroenterological Association in 2021, studies indicate that GERD affects approximately one-third of the population in the U.S..
Pharmaceutical companies utilize direct-to-consumer advertising to enhance consumer awareness of acid-related disorders and available treatment options, including PPIs. This marketing strategy has the potential to generate consumer interest in PPIs and influence the prescribing behaviour of healthcare professionals.
China is set to exhibit a CAGR of 7.3% in the global proton pump inhibitors market during the forecast period. China has a large population of over 1.4 billion people, providing a vast potential consumer base for PPIs. Additionally, there is an increasing prevalence of gastrointestinal disorders in China, including gastroesophageal reflux disease (GERD), contributing to the demand for PPI medications. Furthermore, the Chinese government's initiatives to improve healthcare infrastructure and expand access to medical services have resulted in enhanced healthcare expenditure, facilitating greater access to PPI medications.
Germany held a global market share of around 6.3% in 2022.The outlook for Germany in the proton pump inhibitor (PPI) market is promising. The country's well-established healthcare system, high prevalence of gastroesophageal reflux disease (GERD), and aging population contribute to a steady demand for PPI medications.
Furthermore, obesity has a significant impact on the occurrence and exacerbation of gastroesophageal reflux disease (GERD) among the German population. Individuals classified as obese often have an accumulation of excess adipose tissue in the abdominal area, leading to increased pressure on the stomach. This can result in intra-abdominal or intra-gastric pressure, delays in gastric emptying, and heightened retention of food and stomach acid, increasing the likelihood of acid reflux and GERD symptoms.
According to the World Health Organization (2022), an estimated 59% of adults in the European Region, including Germany, live with overweight or obesity.
Moreover, Germany's robust pharmaceutical industry and advanced healthcare infrastructure support the availability and accessibility of PPIs. Additionally, increasing awareness among healthcare professionals and patients about the effectiveness of PPIs in managing GERD further boosts market growth.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Omeprazole is projected to experience substantial growth with a CAGR of 5.0% by the end of the forecast period, capturing a market share of 28.5% in 2022. Omeprazole has demonstrated remarkable efficacy in reducing stomach acid production by inhibiting the activity of the acid-producing enzyme, offering relief from acid reflux and heartburn symptoms.
Its widespread use and popularity among patients and healthcare professionals can be attributed to its effectiveness. Omeprazole is widely available over the counter (OTC), enabling self-medication for mild symptoms and driving the market growth. The expiration of its patent has led to the emergence of generic versions, increasing accessibility and affordability, and providing a cost-effective alternative for patients and healthcare systems.
The oral route of administration dominated the proton pump inhibitor (PPI) market with a significant market share of 66.3% in 2022 and is projected to grow at a CAGR of 5.0% by the end of the forecast period. Oral PPIs have the advantage of being absorbed into the bloodstream, exerting a systemic effect throughout the body.
In the case of GERD, oral medications effectively reduce stomach acid production, alleviate esophageal inflammation, and promote tissue healing. By inhibiting the enzyme responsible for acid production, these medications provide symptom relief and facilitate esophageal recovery. The convenience of oral dosing allows patients to self-administer at home, leading to improved treatment adherence for the long-term management of GERD.
Capsules capture a significant market share of 39.2% in 2022 and are anticipated to exhibit steady growth with a projected CAGR of 5.1% by 2033. They are favoured by patients due to their ease of swallowing, making them a convenient option for those with difficulty swallowing tablets or a preference for capsules.
The precise dosing capabilities of capsules are valued by consumers as they contain a pre-measured amount of the active ingredient, ensuring accurate and consistent dosing. The protective capsule shell safeguards the medication, preventing degradation and maintaining stability and potency over an extended duration. Consistent and precise delivery of the proton pump inhibitor is vital for optimal acid suppression control.
Generics are projected to experience significant growth with a CAGR of 5.3% by the end of the forecast period, capturing a market share value of 74.3% in 2022. Generic proton pump inhibitors (PPIs) have gained popularity due to their cost-effectiveness compared to brand-name equivalents.
The expiration of patents on branded PPIs has paved the way for affordable generic alternatives, expanding access to a broader patient population. This affordability factor enables healthcare providers to prescribe PPI therapy to individuals who were previously unable to afford brand-name options or had limited insurance coverage. The increased accessibility of cost-effective PPIs has led to the expansion of the potential patient base, driving the market growth.
Gastroesophageal reflux disease (GERD) holds a market share of 49.7% in 2022 and is expected to exhibit gradual growth with a CAGR of 5.0% by 2033. The increasing global prevalence of GERD is a major driver of the demand for proton pump inhibitors (PPIs). GERD is a common medical condition that affects a significant portion of the population. The growing prevalence of GERD can be attributed to various factors, such as lifestyle changes, dietary habits, and the increasing prevalence of obesity. These factors contribute to the rising demand for PPIs as an effective treatment option for managing GERD symptoms and promoting patient well-being.
Hospital pharmacies held the significant market share value of 40.8% in 2022, with a projected CAGR of 5.3% over the forecasted period. With a direct connection to healthcare facilities, hospital pharmacies enjoy advantages such as a captive patient base and close collaboration with healthcare providers. Hospitals often treat patients with complex medical conditions, including those requiring long-term PPI therapy. By stocking and dispensing PPIs, hospital pharmacies fulfill the medication needs of these patients, resulting in a consistent demand for PPIs and increased sales.
Moreover, hospital pharmacies can provide specialized pharmaceutical care and clinical support, further enhancing their position as a key distribution channel for PPIs in the global market.
The Proton Pump Inhibitors (PPI) market is highly competitive, with major players actively pursuing market expansion in emerging economies through strategic partnerships, mergers, and acquisitions. These companies are also focused on developing and introducing innovative and advanced products. Our analysis of the competitive landscape indicates the presence of both global and local players that hold significant market shares. These companies not only engage in collaborations with other key market participants but also pursue acquisitions and mergers to strengthen their market presence.
Some key instances of development include:
Similarly, the team at Future Market Insights has tracked recent developments related to companies in the photon pump inhibitors market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | USD Million for Value |
| Key Countries Covered | U.S., Canada, Brazil, Argentina, Mexico, Germany, France, U.K., Italy, Spain, Russia, BENELUX, Nordic Countries, Poland, Switzerland, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | By Drug Type, By Route of Administration, By Dosage Form, By Prescription Type, By Indication, By Distribution Channel, and By Region |
| Key Companies Covered |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
Demand for proton pump inhibitors globally is forecasted to surge at 5.2% CAGR through 2033.
The net worth of market in 2023 is estimated to be around US$ 3 billion.
Omeprazole is the popular drug segment with 28.5% market share in 2022.
Capsules favor the higher use of Proton Pump Inhibitors and had 39.2% market share in 2022.
The United States market is poised to lead with almost 34.4% market share in 2023.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Value-Added Insights
4.1. Product Adoption and Usage Analysis-By Region
4.2. Disease Epidemiology-By Key Indication
4.3. Regulatory Landscape-by Country
4.4. Reimbursement Outlook
4.5. New Drug Launches & Approvals
4.6. Pipeline Assessment
4.7. Value Chain Analysis
4.8. Regional PESTLE Analysis
4.9. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global Rise in Healthcare Spending
5.1.2. Global Pharmaceutical Market Outlook
5.1.3. Global Lifescience Market Outlook
5.1.4. Global Gastroesophageal Reflux Disease Therapeutics Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising prevalence of gastroesophageal reflux disease (GERD)
5.2.2. Increasing aging population
5.2.3. Growing incidence of Helicobacter pylori infections
5.2.4. Increasing adoption of self-medication
5.2.5. Technological advancements in drug delivery systems
5.2.6. Increasing awareness and Patient education
5.2.7. Expansion of the pharmaceutical industry in emerging markets
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017–2022 and Forecast, 2023 to 2033
6.1. Historical Market Value (US$ Million) Analysis, 2017–2022
6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
6.2.2. Absolute $ Opportunity Analysis
7. Global Market Analysis 2017–2022 and Forecast 2023 to 2033, By Drug Type
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Million) Trends Analysis By Drug Type, 2017–2022
7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
7.3.1. Esomeprazole
7.3.2. Omeprazole
7.3.3. Dexlansoprazole
7.3.4. Pantoprazole
7.3.5. Rabeprazole
7.3.6. Lansoprazole
7.3.7. Others
7.4. Market Attractiveness Analysis By Drug Type
8. Global Market Analysis 2017–2022 and Forecast 2023 to 2033, By Route Administration
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Trends Analysis By Route of Administration, 2017–2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
8.3.1. Oral
8.3.2. Injectable
8.4. Market Attractiveness Analysis By Route Administration
9. Global Market Analysis 2017–2022 and Forecast 2023 to 2033, By Dosage Form
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Trends Analysis By Dosage Form, 2017–2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033
9.3.1. Tablet
9.3.2. Capsules
9.3.3. Injection
9.3.4. Others
9.4. Market Attractiveness Analysis By Dosage Form, 2023 to 2033
10. Global Market Analysis 2017–2022 and Forecast 2023 to 2033, By Prescription Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Trends Analysis By Prescription Type, 2017–2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Prescription Type, 2023 to 2033
10.3.1. Branded
10.3.2. Generics
10.4. Market Attractiveness Analysis By Prescription Type, 2023 to 2033
11. Global Market Analysis 2017–2022 and Forecast 2023 to 2033, By Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Trends Analysis By Indication, 2017–2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
11.3.1. Gastroesophageal Reflux Disease
11.3.2. Heartburn
11.3.3. Peptic ulcers
11.3.4. Others
11.4. Market Attractiveness Analysis By Indication, 2023 to 2033
12. Global Market Analysis 2017–2022 and Forecast 2023 to 2033, By Distribution Channel
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Trends Analysis By Distribution Channel, 2017–2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Drug Stores
12.3.4. Specialty Clinics
12.4. Market Attractiveness Analysis By Distribution Channel
13. Global Market Analysis 2017–2022 and Forecast 2023 to 2033, By Region
13.1. Introduction
13.2. Historical Market Size (US$ Million) Trend Analysis By Region, 2017–2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. East Asia
13.3.5. South Asia
13.3.6. Oceania
13.3.7. Middle East and Africa (MEA)
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2017–2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017–2022
15. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.1.1. By Country
15.1.1.1. U.S.
15.1.1.2. Canada
15.1.2. By Drug Type
15.1.3. By Route of Administration
15.1.4. By Dosage Form
15.1.5. By Prescription Type
15.1.6. By Indication
15.1.7. By Distribution Channel
15.2. Market Attractiveness Analysis
15.2.1. By Country
15.2.2. By Drug Type
15.2.3. By Route of Administration
15.2.4. By Dosage Form
15.2.5. By Prescription Type
15.2.6. By Indication
15.2.7. By Distribution Channel
15.3. Market Trends
15.4. Key Market Participants - Intensity Mapping
15.5. Drivers and Restraints - Impact Analysis
15.6. Country Level Analysis & Forecast
15.6.1. U.S. Market Analysis
15.6.1.1. Introduction
15.6.1.2. Market Analysis and Forecast by Market Taxonomy
15.6.1.2.1. By Drug Type
15.6.1.2.2. By Route of Administration
15.6.1.2.3. By Dosage Form
15.6.1.2.4. By Prescription Type
15.6.1.2.5. By Indication
15.6.1.2.6. By Distribution Channel
15.6.2. Canada Market Analysis
15.6.2.1. Introduction
15.6.2.2. Market Analysis and Forecast by Market Taxonomy
15.6.2.2.1. By Drug Type
15.6.2.2.2. By Route of Administration
15.6.2.2.3. By Dosage Form
15.6.2.2.4. By Prescription Type
15.6.2.2.5. By Indication
15.6.2.2.6. By Distribution Channel
16. Latin America Market Analysis 2017–2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017–2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. Mexico
16.3.1.2. Brazil
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Drug Type
16.3.3. By Route of Administration
16.3.4. By Dosage Form
16.3.5. By Prescription Type
16.3.6. By Indication
16.3.7. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Type
16.4.3. By Route of Administration
16.4.4. By Dosage Form
16.4.5. By Prescription Type
16.4.6. By Indication
16.4.7. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Mexico Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Drug Type
16.8.1.2.2. By Route of Administration
16.8.1.2.3. By Dosage Form
16.8.1.2.4. By Prescription Type
16.8.1.2.5. By Indication
16.8.1.2.6. By Distribution Channel
16.8.2. Brazil Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Drug Type
16.8.2.2.2. By Route of Administration
16.8.2.2.3. By Dosage Form
16.8.2.2.4. By Prescription Type
16.8.2.2.5. By Indication
16.8.2.2.6. By Distribution Channel
16.8.3. Argentina Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Drug Type
16.8.3.2.2. By Route of Administration
16.8.3.2.3. By Dosage Form
16.8.3.2.4. By Prescription Type
16.8.3.2.5. By Indication
16.8.3.2.6. By Distribution Channel
17. Europe Market Analysis 2017–2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017–2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. U.K.
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Nordic Countries
17.3.1.9. Poland
17.3.1.10. Switzerland
17.3.1.11. Rest of Europe
17.3.2. By Drug Type
17.3.3. By Route of Administration
17.3.4. By Dosage Form
17.3.5. By Prescription Type
17.3.6. By Indication
17.3.7. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Type
17.4.3. By Route of Administration
17.4.4. By Dosage Form
17.4.5. By Prescription Type
17.4.6. By Indication
17.4.7. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Germany Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Drug Type
17.8.1.2.2. By Route of Administration
17.8.1.2.3. By Dosage Form
17.8.1.2.4. By Prescription Type
17.8.1.2.5. By Indication
17.8.1.2.6. By Distribution Channel
17.8.2. Italy Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Drug Type
17.8.2.2.2. By Route of Administration
17.8.2.2.3. By Dosage Form
17.8.2.2.4. By Prescription Type
17.8.2.2.5. By Indication
17.8.2.2.6. By Distribution Channel
17.8.3. France Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Drug Type
17.8.3.2.2. By Route of Administration
17.8.3.2.3. By Dosage Form
17.8.3.2.4. By Prescription Type
17.8.3.2.5. By Indication
17.8.3.2.6. By Distribution Channel
17.8.4. Nordic Countries Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Drug Type
17.8.4.2.2. By Drug Type
17.8.4.2.3. By Route of Administration
17.8.4.2.4. By Dosage Form
17.8.4.2.5. By Prescription Type
17.8.4.2.6. By Indication
17.8.4.2.7. By Distribution Channel
17.8.5. U.K. Market Analysis
17.8.5.1. Introduction
17.8.5.2. Market Analysis and Forecast by Market Taxonomy
17.8.5.2.1. By Drug Type
17.8.5.2.2. By Route of Administration
17.8.5.2.3. By Dosage Form
17.8.5.2.4. By Prescription Type
17.8.5.2.5. By Indication
17.8.5.2.6. By Distribution Channel
17.8.6. Spain Market Analysis
17.8.6.1. Introduction
17.8.6.2. Market Analysis and Forecast by Market Taxonomy
17.8.6.2.1. By Drug Type
17.8.6.2.2. By Route of Administration
17.8.6.2.3. By Dosage Form
17.8.6.2.4. By Prescription Type
17.8.6.2.5. By Indication
17.8.6.2.6. By Distribution Channel
17.8.7. Benelux Market Analysis
17.8.7.1. Introduction
17.8.7.2. Market Analysis and Forecast by Market Taxonomy
17.8.7.2.1. By Drug Type
17.8.7.2.2. By Route of Administration
17.8.7.2.3. By Dosage Form
17.8.7.2.4. By Prescription Type
17.8.7.2.5. By Indication
17.8.7.2.6. By Distribution Channel
17.8.8. Russia Market Analysis
17.8.8.1. Introduction
17.8.8.2. Market Analysis and Forecast by Market Taxonomy
17.8.8.2.1. By Drug Type
17.8.8.2.2. By Route of Administration
17.8.8.2.3. By Dosage Form
17.8.8.2.4. By Prescription Type
17.8.8.2.5. By Indication
17.8.8.2.6. By Distribution Channel
17.8.9. Nordic Countries Market Analysis
17.8.9.1. Introduction
17.8.9.2. Market Analysis and Forecast by Market Taxonomy
17.8.9.2.1. By Drug Type
17.8.9.2.2. By Route of Administration
17.8.9.2.3. By Dosage Form
17.8.9.2.4. By Prescription Type
17.8.9.2.5. By Indication
17.8.9.2.6. By Distribution Channel
17.8.10. Poland Market Analysis
17.8.10.1. Introduction
17.8.10.2. Market Analysis and Forecast by Market Taxonomy
17.8.10.2.1. By Drug Type
17.8.10.2.2. By Route of Administration
17.8.10.2.3. By Dosage Form
17.8.10.2.4. By Prescription Type
17.8.10.2.5. By Indication
17.8.10.2.6. By Distribution Channel
17.8.11. Switzerland Market Analysis
17.8.11.1. Introduction
17.8.11.2. Market Analysis and Forecast by Market Taxonomy
17.8.11.2.1. By Drug Type
17.8.11.2.2. By Route of Administration
17.8.11.2.3. By Dosage Form
17.8.11.2.4. By Prescription Type
17.8.11.2.5. By Indication
17.8.11.2.6. By Distribution Channel
18. East Asia Market Analysis 2017–2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017–2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Drug Type
18.3.3. By Route of Administration
18.3.4. By Dosage Form
18.3.5. By Prescription Type
18.3.6. By Indication
18.3.7. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Type
18.4.3. By Route of Administration
18.4.4. By Dosage Form
18.4.5. By Prescription Type
18.4.6. By Indication
18.4.7. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. China Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Drug Type
18.8.1.2.2. By Route of Administration
18.8.1.2.3. By Dosage Form
18.8.1.2.4. By Prescription Type
18.8.1.2.5. By Indication
18.8.1.2.6. By Distribution Channel
18.8.2. Japan Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Drug Type
18.8.2.2.2. By Route of Administration
18.8.2.2.3. By Dosage Form
18.8.2.2.4. By Prescription Type
18.8.2.2.5. By Indication
18.8.2.2.6. By Distribution Channel
18.8.3. South Korea Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Drug Type
18.8.3.2.2. By Route of Administration
18.8.3.2.3. By Dosage Form
18.8.3.2.4. By Prescription Type
18.8.3.2.5. By Indication
18.8.3.2.6. By Distribution Channel
19. South Asia Market Analysis 2017–2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017–2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Malaysia
19.3.1.4. Thailand
19.3.1.5. Rest of South Asia
19.3.2. By Drug Type
19.3.3. By Route of Administration
19.3.4. By Dosage Form
19.3.5. By Prescription Type
19.3.6. By Indication
19.3.7. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Type
19.4.3. By Route of Administration
19.4.4. By Dosage Form
19.4.5. By Prescription Type
19.4.6. By Indication
19.4.7. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. India Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Drug Type
19.8.1.2.2. By Route of Administration
19.8.1.2.3. By Dosage Form
19.8.1.2.4. By Prescription Type
19.8.1.2.5. By Indication
19.8.1.2.6. By Distribution Channel
19.8.2. Indonesia Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Drug Type
19.8.2.2.2. By Route of Administration
19.8.2.2.3. By Dosage Form
19.8.2.2.4. By Prescription Type
19.8.2.2.5. By Indication
19.8.2.2.6. By Distribution Channel
19.8.3. Malaysia Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.4. By Drug Type
19.8.5. By Route of Administration
19.8.6. By Dosage Form
19.8.7. By Prescription Type
19.8.8. By Indication
19.8.9. By Distribution Channel
19.8.10. Thailand Market Analysis
19.8.10.1. Introduction
19.8.10.2. Market Analysis and Forecast by Market Taxonomy
19.8.10.2.1. By Drug Type
19.8.10.2.2. By Route of Administration
19.8.10.2.3. By Dosage Form
19.8.10.2.4. By Prescription Type
19.8.10.2.5. By Indication
19.8.10.2.6. By Distribution Channel
20. Oceania Market Analysis 2017-2022 and Forecast 2023-2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017–2022
20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Drug Type
20.3.3. By Route of Administration
20.3.4. By Dosage Form
20.3.5. By Prescription Type
20.3.6. By Indication
20.3.7. By Distribution Channel
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Drug Type
20.4.3. By Route of Administration
20.4.4. By Dosage Form
20.4.5. By Prescription Type
20.4.6. By Indication
20.4.7. By Distribution Channel
20.5. Market Trends
20.6. Key Market Participants - Intensity Mapping
20.7. Drivers and Restraints - Impact Analysis
20.8. Country Level Analysis & Forecast
20.8.1. Australia Market Analysis
20.8.1.1. Introduction
20.8.1.2. Market Analysis and Forecast by Market Taxonomy
20.8.1.2.1. By Drug Type
20.8.1.2.2. By Route of Administration
20.8.1.2.3. By Dosage Form
20.8.1.2.4. By Prescription Type
20.8.1.2.5. By Indication
20.8.1.2.6. By Distribution Channel
20.8.2. New Zealand Market Analysis
20.8.2.1. Introduction
20.8.2.2. Market Analysis and Forecast by Market Taxonomy
20.8.2.2.1. By Drug Type
20.8.2.2.2. By Route of Administration
20.8.2.2.3. By Dosage Form
20.8.2.2.4. By Prescription Type
20.8.2.2.5. By Indication
20.8.2.2.6. By Distribution Channel
21. Middle East and Africa (MEA) Market Analysis 2017–2022 and Forecast 2023 to 2033
21.1. Introduction
21.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017–2022
21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Türkiye
21.3.1.3. Northern Africa
21.3.1.4. South Africa
21.3.1.5. Rest of Middle East and Africa
21.3.2. By Drug Type
21.3.3. By Route of Administration
21.3.4. By Dosage Form
21.3.5. By Prescription Type
21.3.6. By Indication
21.3.7. By Distribution Channel
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Drug Type
21.4.3. By Route of Administration
21.4.4. By Dosage Form
21.4.5. By Prescription Type
21.4.6. By Indication
21.4.7. By Distribution Channel
21.5. Market Trends
21.6. Key Market Participants - Intensity Mapping
21.7. Drivers and Restraints - Impact Analysis
21.8. Country Level Analysis & Forecast
21.8.1. GCC Countries Market Analysis
21.8.1.1. Introduction
21.8.1.2. Market Analysis and Forecast by Market Taxonomy
21.8.1.2.1. By Drug Type
21.8.1.2.2. By Route of Administration
21.8.1.2.3. By Dosage Form
21.8.1.2.4. By Prescription Type
21.8.1.2.5. By Indication
21.8.1.2.6. By Distribution Channel
21.8.2. Türkiye Market Analysis
21.8.2.1. Introduction
21.8.2.2. Market Analysis and Forecast by Market Taxonomy
21.8.2.2.1. By Drug Type
21.8.2.2.2. By Route of Administration
21.8.2.2.3. By Dosage Form
21.8.2.2.4. By Prescription Type
21.8.2.2.5. By Indication
21.8.2.2.6. By Distribution Channel
21.8.3. Northern Africa Market Analysis
21.8.3.1. Introduction
21.8.3.2. Market Analysis and Forecast by Market Taxonomy
21.8.3.2.1. By Drug Type
21.8.3.2.2. By Route of Administration
21.8.3.2.3. By Dosage Form
21.8.3.2.4. By Prescription Type
21.8.3.2.5. By Indication
21.8.3.2.6. By Distribution Channel
21.8.4. South Africa Market Analysis
21.8.4.1. Introduction
21.8.4.2. Market Analysis and Forecast by Market Taxonomy
21.8.4.2.1. By Drug Type
21.8.4.2.2. By Route of Administration
21.8.4.2.3. By Dosage Form
21.8.4.2.4. By Prescription Type
21.8.4.2.5. By Indication
21.8.4.2.6. By Distribution Channel
22. Market Structure Analysis
22.1. Market Analysis by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Concentration
22.4. Market Presence Analysis
22.4.1. Regional Footprint Analysis
22.4.2. Product Footprint Analysis
22.4.3. Channel Footprint Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Branding and Promotional Strategies, Key Players
23.3. Key Development Analysis
23.4. Competition Deep Dive
23.4.1. AstraZeneca
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Sales Footprint
23.4.1.4. Key Developments
23.4.1.5. SWOT Analysis
23.4.1.6. Strategy Overview
23.4.1.6.1. Marketing Strategies
23.4.1.6.2. Product Strategies
23.4.1.6.3. Channel Strategies
23.4.2. Bayer AG
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Sales Footprint
23.4.2.4. Key Developments
23.4.2.5. SWOT Analysis
23.4.2.6. Strategy Overview
23.4.2.6.1. Marketing Strategies
23.4.2.6.2. Product Strategies
23.4.2.6.3. Channel Strategies
23.4.3. Cadila Pharmaceuticals
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Sales Footprint
23.4.3.4. Key Developments
23.4.3.5. SWOT Analysis
23.4.3.6. Strategy Overview
23.4.3.6.1. Marketing Strategies
23.4.3.6.2. Product Strategies
23.4.3.6.3. Channel Strategies
23.4.4. Eisai Inc.
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Sales Footprint
23.4.4.4. Key Developments
23.4.4.5. SWOT Analysis
23.4.4.6. Strategy Overview
23.4.4.6.1. Marketing Strategies
23.4.4.6.2. Product Strategies
23.4.4.6.3. Channel Strategies
23.4.5. GlaxoSmithKline PLC
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Sales Footprint
23.4.5.4. Key Developments
23.4.5.5. SWOT Analysis
23.4.5.6. Strategy Overview
23.4.5.6.1. Marketing Strategies
23.4.5.6.2. Product Strategies
23.4.5.6.3. Channel Strategies
23.4.6. Pfizer Inc.
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Sales Footprint
23.4.6.4. Key Developments
23.4.6.5. SWOT Analysis
23.4.6.6. Strategy Overview
23.4.6.6.1. Marketing Strategies
23.4.6.6.2. Product Strategies
23.4.6.6.3. Channel Strategies
23.4.7. Takeda Pharmaceuticals
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Sales Footprint
23.4.7.4. Key Developments
23.4.7.5. SWOT Analysis
23.4.7.6. Strategy Overview
23.4.7.6.1. Marketing Strategies
23.4.7.6.2. Product Strategies
23.4.7.6.3. Channel Strategies
23.4.8. Sanofi SA
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Sales Footprint
23.4.8.4. Key Developments
23.4.8.5. SWOT Analysis
23.4.8.6. Strategy Overview
23.4.8.6.1. Marketing Strategies
23.4.8.6.2. Product Strategies
23.4.8.6.3. Channel Strategies
23.4.9. Perrigo Company PLC
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Sales Footprint
23.4.9.4. Key Developments
23.4.9.5. SWOT Analysis
23.4.9.6. Strategy Overview
23.4.9.6.1. Marketing Strategies
23.4.9.6.2. Product Strategies
23.4.9.6.3. Channel Strategies
23.4.10. Dr. Reddy's Laboratories
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Sales Footprint
23.4.10.4. Key Developments
23.4.10.5. SWOT Analysis
23.4.10.6. Strategy Overview
23.4.10.6.1. Marketing Strategies
23.4.10.6.2. Product Strategies
23.4.10.6.3. Channel Strategies
23.4.11. Redhill Pharma Limited
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Sales Footprint
23.4.11.4. Key Developments
23.4.11.5. SWOT Analysis
23.4.11.6. Strategy Overview
23.4.11.6.1. Marketing Strategies
23.4.11.6.2. Product Strategies
23.4.11.6.3. Channel Strategies
23.4.12. Cipla Limited
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Sales Footprint
23.4.12.4. Key Developments
23.4.12.5. SWOT Analysis
23.4.12.6. Strategy Overview
23.4.12.6.1. Marketing Strategies
23.4.12.6.2. Product Strategies
23.4.12.6.3. Channel Strategies
24. Assumptions and Acronyms Used
25. Research Methodology
Healthcare
March 2023
REP-GB-16787
301 pages
Explore Healthcare Insights
View Reports
Proton Pump Inhibitors Market
